- Conditions
- Tuberous Sclerosis Complex
- Interventions
- Early Vigabatrin, Delayed Vigabatrin (Placebo)
- Drug
- Lead sponsor
- Martina Bebin
- Other
- Eligibility
- 1 Day to 6 Months
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Post-surgical Pain
- Interventions
- AYX1 Injection 660 mg/6 mL, Placebo Injection 6 mL
- Drug
- Lead sponsor
- Adynxx, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 6 more
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- Sotorasib, Panitumumab, Trifluridine and Tipiracil, Regorafenib
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Duarte, California • Orange, California + 16 more
- Conditions
- Breast Cancer
- Interventions
- Imaging Drug FluorThanatrace (FTT)
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Parkinson's Disease
- Interventions
- Accordion Pill™ Carbidopa/Levodopa, Sinemet®, Placebo -AP-CD/LD, Placebo- Sinemet
- Drug
- Lead sponsor
- Intec Pharma Ltd.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 32 more
- Conditions
- Covid19
- Interventions
- TQ Formula/Tab
- Drug
- Lead sponsor
- Novatek Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- San Diego, California • Hialeah, Florida • Houston, Texas
- Conditions
- Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
- Interventions
- Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- HIV Infections
- Interventions
- Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 3 Months to 16 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 7
- States / cities
- St. Petersburg, Florida • New Orleans, Louisiana • Great Neck, New York + 4 more
- Conditions
- Lymphoma
- Interventions
- Bendamustine, Obinutuzumab, Polatuzumab vedotin (Liquid), Rituximab, Polatuzumab vedotin (Lyophilized)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Duarte, California + 13 more
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- E/C/F/TDF, COBI, ATV, DRV, NRTI
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
- Conditions
- Sleep, Sleep Disturbance, Sleep Disorder
- Interventions
- Radicle Rest Placebo Control Form 1, Radicle Rest Active Study Product 1.1 Usage, Radicle Rest Placebo Control Form 2, Radicle Rest Active Study Product 2.1 Usage, Radicle Rest Placebo Control 4.1.0, Radicle Rest Active Study Product 4.1.1 Usage
- Dietary Supplement
- Lead sponsor
- Radicle Science
- Industry
- Eligibility
- 21 Years to 105 Years
- Enrollment
- 1,646 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Del Mar, California
- Conditions
- Serious Bacterial Infection
- Interventions
- ATM-AVI, BAT
- Combination Product · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
- Interventions
- AZD9291
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 603 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 3 more
- Conditions
- Neuromuscular Blockade
- Interventions
- Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
- Conditions
- Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
- Interventions
- R932333, Placebo
- Drug
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Redwood City, California • South Bend, Indiana + 9 more
- Conditions
- Hyperkalemia
- Interventions
- Patiromer Powder for Oral Suspension [Veltassa], Placebo
- Drug
- Lead sponsor
- Comprehensive Research Associates
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 19
- States / cities
- Stanford, California • New Haven, Connecticut • Newark, Delaware + 13 more
- Conditions
- Smoking, Homeless Persons
- Interventions
- Bupropion, Nicotine replacement therapy, Contingency Management
- Drug · Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Coronary Heart Disease, Myocardial Infarction
- Interventions
- Titration of medications, Lifestyle Counseling, Medication Counseling, Usual Care with Medication Reconciliation
- Other · Behavioral
- Lead sponsor
- Middle Tennessee Research Institute
- Other
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Healthy Recreational Drug Users
- Interventions
- ACT-541468, Suvorexant, Zolpidem, Placebo
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Sunscreening Agents
- Interventions
- CAP Unscented
- Drug
- Lead sponsor
- HALEON
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Piscataway, New Jersey
- Conditions
- Metabolic Health
- Interventions
- Placebo Metabolic Control 1, Active Metabolic Product 1
- Dietary Supplement
- Lead sponsor
- Radicle Science
- Industry
- Eligibility
- 21 Years to 105 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Del Mar, California
- Conditions
- Acute Heart Failure
- Interventions
- Liraglutide, Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 25
- States / cities
- Newark, Delaware • Atlanta, Georgia • Chicago, Illinois + 14 more
- Conditions
- Orthostatic Hypotension, Parkinson's Disease
- Interventions
- Droxidopa, Placebo
- Drug · Other
- Lead sponsor
- Chelsea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 60
- States / cities
- Alabaster, Alabama • Gilbert, Arizona • Phoenix, Arizona + 53 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan, Abemaciclib, Fulvestrant, Ribociclib (Dose #1), Inavolisib (Dose #1), Trastuzumab Deruxtecan, Ribociclib (Dose #2), Letrozole, Inavolisib (Dose #2), Empagliflozin, Palbociclib, Metformin, Atirmociclib, Giredestrant
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 24
- States / cities
- Duarte, California • Irvine, California • La Jolla, California + 18 more